Strong CD8 T-cell responses following coimmunization with plasmids expressing the dominant pp89 and subdominant M84 antigens of murine cytomegalovirus correlate with long-term protection against subsequent viral challenge.
We previously showed that intradermal immunization with plasmids expressing the murine cytomegalovirus (MCMV) protein IE1-pp89 or M84 protects against viral challenge and that coimmunization has a synergistic protective effect (C. S. Morello, L. D. Cranmer, and D. H. Spector, J. Virol. 74:3696-3708, 2000). Using an intracellular gamma interferon cytokine staining assay, we have now characterized the CD8+ T-cell response after DNA immunization with pp89, M84, or pp89 plus M84. The pp89- and M84-specific CD8+ T-cell responses peaked rapidly after three immunizations. DNA immunization and MCMV infection generated similar levels of pp89-specific CD8+ T cells. In contrast, a significantly higher level of M84-specific CD8+ T cells was elicited by DNA immunization than by MCMV infection. Fusion of ubiquitin to pp89 enhanced the CD8+ T-cell response only under conditions where vaccination was suboptimal. Three immunizations with either pp89, M84, or pp89 plus M84 DNA also provided significant protection against MCMV infection for at least 6 months, with the best protection produced by coimmunization. A substantial percentage of antigen-specific CD8+ T cells remained detectable, and they responded rapidly to the MCMV challenge. These results underscore the importance of considering antigens that do not appear to be highly immunogenic during infection as DNA vaccine candidates.
Ye
Ming
M
Molecular Biology Section, Division of Biology, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0366, USA.
Morello
Christopher S
CS
Spector
Deborah H
DH
D016475:3T3 Cells; D000818:Animals; D000956:Antigens, Viral / Q000235:genetics / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D022482:Cytomegalovirus Vaccines / Q000008:administration & dosage / Q000276:immunology*; D004279:DNA, Viral / Q000276:immunology; D005260:Female; D006566:Herpesviridae Infections / Q000517:prevention & control* / Q000821:virology; D017874:Immediate-Early Proteins / Q000235:genetics / Q000276:immunology*; D007114:Immunization; D007156:Immunologic Memory; D051379:Mice; D008807:Mice, Inbred BALB C; D018146:Muromegalovirus / Q000235:genetics / Q000276:immunology*; D010750:Phosphoproteins / Q000235:genetics / Q000276:immunology*; D010957:Plasmids / Q000235:genetics / Q000276:immunology; D025801:Ubiquitin / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D014763:Viral Matrix Proteins / Q000235:genetics / Q000276:immunology*
D000956:Antigens, Viral; D022482:Cytomegalovirus Vaccines; D004279:DNA, Viral; D017874:Immediate-Early Proteins; C102374:M83 protein, murine cytomegalovirus; D010750:Phosphoproteins; D025801:Ubiquitin; D014763:Viral Matrix Proteins; C052612:cytomegalovirus immediate early phosphoprotein pp89